This article by Dr. Kyle Biggar is the 4th in a series of articles on the Hallmarks of Cancer. This month Dr. Kyle Biggar gives an overview of the hallmark “sustaining proliferative signalling”, and research related to this hallmark taking place in the lab of Dr. Shawn Li that focuses on the issue of chemotherapy sensitivity by targeting a relatively unexplored natural chemical alteration made to proteins referred to as lysine methylation. Read more in the Londoner.